Clearmind Medicine Secures Up to $10M Via Convertible Notes
Ticker: CMND · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1892500
Sentiment: neutral
Topics: financing, convertible-debt, capital-raise
TL;DR
Clearmind Medicine is selling up to $10M in convertible notes to institutional investors.
AI Summary
On September 17, 2025, Clearmind Medicine Inc. entered into securities purchase agreements with institutional investors to issue and sell convertible promissory notes. The aggregate principal amount of these notes can be up to $10,000,000. This move is intended to raise capital for the company.
Why It Matters
This financing could provide Clearmind Medicine with crucial capital to fund its operations and development, potentially impacting its ability to advance its pharmaceutical research.
Risk Assessment
Risk Level: medium — Issuing convertible notes can dilute existing shareholders' equity if converted, and the company's ability to repay or convert the notes depends on its future performance.
Key Numbers
- $10.0M — Convertible Promissory Notes (Maximum aggregate principal amount the company can raise through the sale of notes.)
Key Players & Entities
- Clearmind Medicine Inc. (company) — The company issuing convertible promissory notes.
- September 17, 2025 (date) — Date of the securities purchase agreements.
- $10,000,000 (dollar_amount) — Aggregate principal amount of convertible promissory notes.
FAQ
What is the purpose of the convertible promissory notes?
The filing indicates the notes are being sold to institutional investors, suggesting a capital raise to fund the company's operations or development.
Who are the institutional investors purchasing the notes?
The filing refers to them as 'institutional investors' and 'Holders' but does not name specific entities.
What are the terms of the convertible promissory notes?
The filing states the aggregate principal amount is up to $10,000,000, but specific interest rates, maturity dates, and conversion terms are not detailed in this excerpt.
When were the securities purchase agreements entered into?
The agreements were entered into on September 17, 2025.
What is the filing type and its significance?
This is a Form 6-K, which is a report of foreign private issuers submitted periodically to the SEC, often used to announce material information not otherwise required to be filed on a more formal registration statement.
Filing Stats: 1,470 words · 6 min read · ~5 pages · Grade level 16.7 · Accepted 2025-09-17 16:15:01
Key Financial Figures
- $10,000,000 — the aggregate principal amount of up to $10,000,000 (the “Subscription Amount”)
- $555,556 — te in the aggregate principal amount of $555,556 for a purchase price of $500,000. On th
- $500,000 — unt of $555,556 for a purchase price of $500,000. On the date on which the Registration
- $1,944,444 — es in the aggregate principal amount of $1,944,444 for a purchase price of $1,750,000. Com
- $1,750,000 — t of $1,944,444 for a purchase price of $1,750,000. Commencing on the date that is three m
- $2,500,000 — es in the aggregate principal amount of $2,500,000 for a purchase price of $2,250,000 duri
- $2,250,000 — t of $2,500,000 for a purchase price of $2,250,000 during each subsequent three month peri
- $7,500,000 — gate amount of such additional notes is $7,500,000 for a purchase price of $6,750,000. The
- $6,750,000 — s is $7,500,000 for a purchase price of $6,750,000. The Company intends to use the net pro
- $1.01 — version price equal to the lower of (i) $1.01 and (ii) 12% of the lowest daily volume
- $0.20 — ay not be lower than the floor price of $0.20 per Common Share, which is equal to 20%
Filing Documents
- ea0257692-6k_clearmind.htm (6-K) — 22KB
- ea025769201ex4-1_clearmind.htm (EX-4.1) — 94KB
- ea025769201ex10-1_clearmind.htm (EX-10.1) — 99KB
- 0001213900-25-088566.txt ( ) — 216KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: September 17, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 4